Even non-experts identify non-dysplastic lesions in inflammatory bowel disease via chromoendoscopy: results of a screening program in real-life.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

1. Current status of image-enhanced endoscopy in inflammatory bowel disease.Clinical endoscopy · 2023
   Review
2. Low risk of new dysplastic lesions in an inflammatory bowel disease population study with dye chromoendoscopy.Endoscopy international open · 2023
   Article
3. Endoscopic characterization of neoplastic and non-neoplastic lesions in inflammatory bowel disease: systematic review in the era of advanced endoscopic imaging.Therapeutic advances in gastroenterology · 2023
   Review
4. Evolving roles of magnifying endoscopy and endoscopic resection for neoplasia in inflammatory bowel diseases.World journal of gastrointestinal oncology · 2022
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

16 authors at 5 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.